carfilzomib Articles
US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma
15 May 2013
Batch of mixed opinions from FDA advisory panels
21 June 2012
Onyx falls as FDA says no priority review for cancer drug
13 December 2011
Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report
1 November 2011
Onyx Pharma files NDA for multiple myeloma drug carfilzomib
29 September 2011
Showing 1-9 of 9 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
